AUTHORS
Oksana Karnabeda, MD, Evgen Levenko, MD, PhD2, Isabel Cano-Ferri, MD3, Pau Montesinos, MD4, Cristina Papayannidis, MD, PhD5, Teresa Bernal, MD, PhD6, Ciprian Ionut Tomuleasa, MD, PhD7, Ben Tomlinson, MD8, Janusz Halka, MD, PhD9, Dominik Chraniuk, MD10, Nino Sharashenidze, MD11, Levani Makhaldiani, MD12, Matteo Piccini, MD13, Robert Charles Shepard, MD, FACP14, Paul Waymack, MD, ScD15, Cynthia Abbate, BS16, Erikson Wasyl, MS17
AFFILIATIONS
1 Arensia Exploratory Medicine, Kyiv, Ukraine
2 Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain, Valencia, Spain
3 Hospital Universitari i Politècnic La Fe, Valencia, Spain
4 Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain, Valencia, Spain
5 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
6 Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Oviedo, Spain
7 Oncology Institute 'Prof. Dr. Ion Chiricu?a', Cluj-Napoca, Romania, Cluj-Napoca, Romania
8 University Hospitals, Cleveland, Ohio, United States
9 Clinical Hospital Ministry of Interior and Administration with the Warmia-Masuria Oncology Center, Olsztyn, Poland
10 Wojewódzki Szpital Zespolony im. Ludwika Rydygiera w Toruniu, Torun, Poland
11 Arensia Exploratory Medicine, Tbilisi, Georgia
12 Caucasus Medical Centre, Tbilisi, Georgia
13 SOD Ematologia, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy, Firenze, Italy
14 Moleculin Biotech, Houston, Texas, United States, Moleculin Biotech, Houston, Texas, United States
15 Moleculin Biotech, Houston, Texas, United States
16 Moleculin Biotech, Houston, Texas, United States
17 Moleculin Biotech, Houston, Texas, United States
ABSTRACT
Background: Refractory/relapsed (R/R) AML remains a major unmet need with new therapies achieving only limited success. Naxtarubicin (formerly L-Annamycin) is an anthracycline with no cardiotoxicity observed to date that has shown promise in R/R AML. In the completed phase 1/2 MB-106 trial, intravenous naxtarubicin at 190 or 230 mg/m2 for 3 consecutive days plus cytarabine 2 g/m2 for 5 consecutive days achieved a complete remission (CR) rate of 50% and composite complete remission (CRc) rate of 60% as second-line therapy. No evidence of impaired cardiac function was observed.
MB-108 is a pivotal Phase 2/3 trial authorized in the U.S. and participating European countries to confirm the efficacy and safety findings observed with naxtarubicin at 190 and 230 mg/m² plus cytarabine in MB-106. The FDA that a successful MB-108 clinical trial could be sufficient to support an NDA submission.
Methods: Patients in the U.S. and Europe with ELN-defined R/R AML after one prior line of therapy are randomized to receive placebo, naxtarubicin 190 mg/m2, or naxtarubicin 230 mg/m2 for 3 days, each in combination with cytarabine 2 g/m2 for 5 days. Serial safety assessments include hematology and chemistry monitoring, ECGs, and echocardiograms. A bone marrow biopsy is performed on Day 35±14.
Responses are assessed using protocol-defined criteria based on ELN 2022 recommendations, with FDA-aligned hematologic recovery thresholds. CRc includes CR, CR with partial hematologic recovery (CRh) and CR with incomplete hematologic recovery (CRi). The primary endpoint is CR rate after one treatment cycle. In Part A, this endpoint is used to select the optimal naxtarubicin dose; in Part B, to compare the selected naxtarubicin dose with placebo, each in combination with cytarabine. Power calculations used a one-sided alpha of 0.0249 with an O’Brien-Fleming adjustment for two interim analyses and 80% power, assuming CR rates of 20% in the placebo arm and 35% in the optimal naxtarubicin arm. The secondary efficacy endpoint is the difference in median survival times.
Two interim analyses are prespecified in Part A after 45 and 90 patients complete treatment. At the first, the independent data monitoring committee (iDMC) reviews group-level efficacy outputs to assess futility and recommend whether one or both naxtarubicin dose regimens should continue; at the second, it reviews pooled unblinded efficacy, safety, and PK data to recommend the optimal dose for Part B. In Part B, approximately 222 additional patients will then be randomized 1:1 to the selected dose or placebo, each with cytarabine.
The study is registered on ClinicalTrials.gov (NCT06788756) and in the EU Clinical Trials Information System (EU Trial 2024-518359-47-00).
Results: The prespecified first interim analysis included 45 randomized patients; 76% were aged > 60 years. Prior therapies included 7+3 (cytarabine + an anthracycline) in 56% and venetoclax + azacitidine in 31%.
Following a single treatment cycle, CR rates were 12% (2/17), 43% (6/14) and 36% (5/14) in the placebo, naxtarubicin 190 mg/m2, and naxtarubicin 230 mg/m2 arms, respectively (p=0.158). CRc rates were 29% (5/17), 50% (7/14) and 57% (8/14) (p=0.293). Consistent with findings across the naxtarubicin clinical program to date, no signs, symptoms or echocardiographic findings suggestive of cardiotoxicity were observed through the data cutoff.
The iDMC recommended that the trial continue without amendment, with all three arms maintained. Data from the second interim analysis are expected in early 2027.
Conclusions: The first interim evaluation of the data from the initial 45 patients in this trial is consistent with prior MB-106 clinical trial results. These initial results also documented an efficacy rate in the control arm less than was assumed and in the naxtarubicin arms greater than was assumed for the protocol’s power calculations. To that end, statistical optimism appears justified and the study will therefore continue without amendments.
DISCLOSURES
Robert Charles Shepard, MD, FACP: Moleculin Biotech, Inc. - Current equity holder in publicly-traded company; Moleculin Biotech, Inc. - Current equity holder in publicly-traded company; Moleculin Biotech, Inc. - Current Employment; Moleculin Biotech, Inc. - Current Employment